Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Inc. specializes in developing innovative oncology therapies, focusing on lasofoxifene, a selective estrogen receptor modulator for treating breast cancer in women, particularly targeting those with specific genetic mutations. Founded in 2014 in Columbus, US, Sermonix Pharmaceuticals Inc. is dedicated to advancing female-specific oncology products.

Led by CEO David Portman, the company has raised a total of USD 40. 23 mn through 3 funding rounds, with the latest Series A round completed on November 12, 2021, led by Perceptive Advisors. The firm does not have any known subsidiaries or parent companies. Sermonix Pharmaceuticals specializes in developing and commercializing female-specific oncology products, primarily focusing on lasofoxifene, a selective estrogen receptor modulator (SERM) aimed at treating breast cancer.

Lasofoxifene is currently under investigation for its effectiveness in postmenopausal and premenopausal women with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer with an ESR1 mutation. The company aims to improve progression-free survival rates compared to existing therapies, targeting markets in North America and Europe, where the need for innovative breast cancer treatments is growing. Sermonix Pharmaceuticals generates revenue by commercializing its oncology products and forming partnerships with healthcare providers and research institutions for clinical trials and distribution. The company employs a B2B model, collaborating with hospitals, oncology clinics, and healthcare networks to deliver therapies directly to healthcare professionals.

The pricing for lasofoxifene and related services is influenced by market conditions and therapeutic benefits, allowing healthcare providers to offer advanced treatment options. Furthermore, Sermonix is exploring collaborations and partnerships to enhance its revenue through joint clinical initiatives. Sermonix Pharmaceuticals Inc. plans to utilize the recent funding of USD 40.

23 mn raised in November 2021 to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM for treating women with prevalent ESR1 breast cancer mutations. The company aims to expand into new markets, specifically targeting regions with high breast cancer incidence, and is focused on enhancing its product offerings to meet the needs of healthcare providers. Future initiatives will build on the current partnerships to facilitate access to innovative treatment options.